Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

When antidepressants don't work, five days could change that

(BPT) - Finding a medication that alleviates major depression can often take months or years: try a dose, wait, adjust, wait again. And for many, antidepressants simply don't provide lasting relief. During that time, symptoms can disrupt work, family life and even basic daily functioning.

A new, non-invasive treatment called SAINT® (Stanford Accelerated Intelligent Neuromodulation Therapy), licensed exclusively to Magnus Medical from Stanford University, is the first FDA-cleared, clinically proven therapy that provides rapid relief for people with major depressive disorder (MDD).

For those with treatment-resistant major depression - a condition impacting more than half of people with depression who don't respond to medications and psychotherapy - that difference in timing can be lifesaving.

Man wearing glasses looking out the window.


SAINT delivers medication-free relief almost immediately. Each day of the five-day course consists of 10 short sessions of stimulation, guided by a magnetic resonance imaging (MRI) map of the individual's brain.

In published clinical trials with SAINT, nearly 8 out of 10 participants went into remission from their depression in as few as 2.6 days, with a majority staying well for months.

Doctors say the people who qualify for SAINT have typically tried several antidepressants without satisfactory improvement and are looking for a non-drug intervention that doesn't require hospitalization. These are people who have suffered from life-altering depression that has long impacted their quality of life.

Brandon Bentzley, M.D., Ph.D., a psychiatrist who helped develop SAINT at Stanford, says the goal is precise, rapid relief. "SAINT therapy has already shown the ability to rapidly lift depressive symptoms without systemic side effects, offering hope for a safer, faster solution that helps people feel like themselves again."

What makes SAINT different from other treatments is the combination of personalization, speed of treatment response and high rates of clinical remission. Before treatment starts, doctors use MRI to pinpoint the unique spot in each person's brain for treatment, then deliver an outpatient course of brief, precisely targeted stimulation sessions, all completed within a single work week.

Woman leaning against a wall and looking upward.


What do patients often report feeling after the treatment?

Doctors, including Bentzley, say many describe the quieting of racing or repetitive negative thoughts, the first solid night of sleep in months, and a "fog lifting" that makes basic tasks like showering, stepping outside, and creating a simple meal feel doable again.

For most, suicidal thoughts go away, and others report steadier mood and better focus. Families of SAINT patients commonly notice increased eye contact, conversation, and a greater interest in everyday activities soon after treatment begins.

Man outside with a cloud behind him tilting his head up with his eyes closed.


Where do I find SAINT?

SAINT is available at leading health systems, private clinics and medical research centers nationwide. Designated a breakthrough device by the FDA, SAINT is the first mental health therapy to receive innovation support from the Centers for Medicare & Medicaid Services (CMS) through the New Technology Add-on Payment (NTAP) and New Technology Ambulatory Payment Classification (APC) programs, which have helped hospitals and clinics make it easily accessible.

Many commercial insurers approve treatment after medical review, often with prior authorization.

If standard depression treatments have not been effective for you or a family member, talk with your healthcare provider about SAINT. Providers offering SAINT therapy may be found by visiting MagnusMed.com/provider-locator.

Looking ahead

"The future of mental health is precision medicine - treatments that work quickly and effectively," Bentzley says. "SAINT is proof we're heading there now."

If you are in a crisis, call or text 988 to reach the Suicide & Crisis Lifeline, or chat via 988lifeline.org.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.